Search Results

Cellmid Limited (ASX: CDY) is pleased to advise that the prestigious Journal of Experimental Medicine has published a highly significant study showing for the first time that midkine, around which the Company holds extensive intellectual property rights, promotes cardiac muscle inflammation associated with the occasionally fatal autoimmune disease, myocarditis

Cellmid Limited today advised that the Share Purchase Plan (“SPP”) announced on 31 July 2018 with an offer price of $0.38 has now closed.

Brand protection and customer connection solutions company YPB Group Ltd and life sciences company Cellmid have signed an agreement to utilise the YPB CONNECT Consumer Connection SaaS platform in the marketing of Cellmid’s evolis hair loss products in China.

Customer receipts for the first quarter of FY2019 at $2.01 million, up 100% from the same period in FY2018 ($1.01 million)